117 related articles for article (PubMed ID: 35006781)
1. Biomimetic Polymer-Templated Copper Nanoparticles Stabilize a Temozolomide Intermediate for Chemotherapy against Glioblastoma Multiforme.
Wang X; Hu A; Du K; Feng F
ACS Appl Bio Mater; 2021 Nov; 4(11):8004-8012. PubMed ID: 35006781
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme.
Li X; Shao F; Sun J; Du K; Sun Y; Feng F
ACS Appl Mater Interfaces; 2019 Nov; 11(45):41935-41945. PubMed ID: 31644262
[TBL] [Abstract][Full Text] [Related]
3. Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy.
Du K; Xia Q; Sun J; Feng F
ACS Appl Mater Interfaces; 2021 Dec; 13(47):55851-55861. PubMed ID: 34788006
[TBL] [Abstract][Full Text] [Related]
4. Polymer-Drug Conjugates Codeliver a Temozolomide Intermediate and Nitric Oxide for Enhanced Chemotherapy against Glioblastoma Multiforme.
Du K; Li X; Feng F
ACS Appl Bio Mater; 2024 Mar; 7(3):1810-1819. PubMed ID: 38403964
[TBL] [Abstract][Full Text] [Related]
5. Chemoattractants driven and microglia based biomimetic nanoparticle treating TMZ-resistant glioblastoma multiforme.
Qiao S; Cheng Y; Liu M; Ji Q; Zhang B; Mei Q; Liu D; Zhou S
J Control Release; 2021 Aug; 336():54-70. PubMed ID: 34129862
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.
Petrenko D; Chubarev V; Syzrantsev N; Ismail N; Merkulov V; Sologova S; Grigorevskikh E; Smolyarchuk E; Alyautdin R
Molecules; 2022 May; 27(11):. PubMed ID: 35684445
[TBL] [Abstract][Full Text] [Related]
7. Induction Therapy of Retinoic Acid with a Temozolomide-Loaded Gold Nanoparticle-Associated Ultrasound Effect on Glioblastoma Cancer Stem-Like Colonies.
Fadera S; Chen PY; Liu HL; Lee IC
ACS Appl Mater Interfaces; 2021 Jul; 13(28):32845-32855. PubMed ID: 34235925
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy.
Du K; Xia Q; Heng H; Feng F
ACS Appl Mater Interfaces; 2020 Aug; 12(31):34599-34609. PubMed ID: 32648735
[TBL] [Abstract][Full Text] [Related]
9. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
10. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
Kim SS; Rait A; Kim E; Pirollo KF; Chang EH
Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597
[TBL] [Abstract][Full Text] [Related]
11. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.
Delello Di Filippo L; Hofstätter Azambuja J; Paes Dutra JA; Tavares Luiz M; Lobato Duarte J; Nicoleti LR; Olalla Saad ST; Chorilli M
Eur J Pharm Biopharm; 2021 Nov; 168():76-89. PubMed ID: 34461214
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide resistance in glioblastoma multiforme.
Lee SY
Genes Dis; 2016 Sep; 3(3):198-210. PubMed ID: 30258889
[TBL] [Abstract][Full Text] [Related]
13. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy.
Ramalho MJ; Andrade S; Coelho MÁN; Loureiro JA; Pereira MC
Eur J Pharm Biopharm; 2019 Mar; 136():156-163. PubMed ID: 30682492
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Efficacy of Temozolomide Loaded by a Tetrahedral Framework DNA Nanoparticle in the Therapy for Glioblastoma.
Fu W; You C; Ma L; Li H; Ju Y; Guo X; Shi S; Zhang T; Zhou R; Lin Y
ACS Appl Mater Interfaces; 2019 Oct; 11(43):39525-39533. PubMed ID: 31601097
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment targeting for glioblastoma multiforme treatment via hybrid cell membrane coating supramolecular micelles.
Huang X; Mu N; Ding Y; Huang R; Wu W; Li L; Chen T
J Control Release; 2024 Feb; 366():194-203. PubMed ID: 38142965
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.
Tsang LL; Quarterman CP; Gescher A; Slack JA
Cancer Chemother Pharmacol; 1991; 27(5):342-6. PubMed ID: 1998993
[TBL] [Abstract][Full Text] [Related]
18. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide nanoparticles for targeted glioblastoma therapy.
Fang C; Wang K; Stephen ZR; Mu Q; Kievit FM; Chiu DT; Press OW; Zhang M
ACS Appl Mater Interfaces; 2015 Apr; 7(12):6674-82. PubMed ID: 25751368
[TBL] [Abstract][Full Text] [Related]
20. Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide.
Sukumar UK; Bose RJC; Malhotra M; Babikir HA; Afjei R; Robinson E; Zeng Y; Chang E; Habte F; Sinclair R; Gambhir SS; Massoud TF; Paulmurugan R
Biomaterials; 2019 Oct; 218():119342. PubMed ID: 31326657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
